周霞

摘要：目的 探讨分析对多重耐药鲍曼不动杆菌肺炎患者采用替加环素联合头孢哌酮舒巴坦进行治疗的效果。方法 本次研究对象均选自我院2019年6月到2020年12月期间收治的多重耐药鲍曼不动杆菌肺炎患者共64例，按照双盲法对患者分组，设定其中32例为参照组采用头孢哌酮舒巴坦进行治疗，其余32例作为观察组联合替加环素治疗，观察对两组的治疗情况。结果 比较两组的治疗有效率，观察组高于参照组（P<0.05）;比较两组的血清炎症因子水平，观察组均优于参照组（P<0.05）。结论 根据本次研究的结果可以确认，对多重耐药鲍曼不动杆菌肺炎患者采用替加环素联合头孢哌酮舒巴坦进行治疗的效果更加理想，还可以有效纠正患者的血清炎症因子水平，值得在临床上大规模应用。

关键词：多重耐药鲍曼不动杆菌肺炎;替加环素;头孢哌酮舒巴坦;治疗效果;对比分析

[Abstract]Objective To investigate the effect of tigecycline combined with cefoperazone sulbactam in the treatment of multi drug resistant Acinetobacter baumannii pneumonia. Methods a total of 64 patients with multidrug-resistant Acinetobacter baumannii pneumonia in our hospital from June 2019 to December 2020 were selected and divided into two groups according to double-blind method. 32 patients in the control group were treated with cefoperazone sulbactam，and the other 32 patients in the observation group were treated with tigecycline. Results the effective rate of the two groups was higher than that of the control group（P < 0.05）;the serum inflammatory factor levels of the two groups were better than that of the control group（P < 0.05）. Conclusion according to the results of this study，it can be confirmed that tigecycline combined with cefoperazone sulbactam in the treatment of patients with multi drug resistant Acinetobacter baumannii pneumonia is more ideal，and it can also effectively correct the serum inflammatory factor levels of patients，which is worthy of large-scale clinical application.

[Key words]multi drug resistant Acinetobacter baumannii pneumonia;tigecycline;cefoperazone sulbactam;treatment effect;comparative analysis

鲍曼不动杆菌属于临床上比较常见的一种致病菌，该病菌主要会存在空气、胸腔以及机体呼吸道中【1】。其很容易导致人体出现肺部感染问题，特别是老年人由于机体免疫力较差，对该病菌的抵抗力较差，极易出现多重耐藥鲍曼不动杆菌肺炎。在对该病进行治疗时，采用单一药物治疗的效果并不是很理想，这就需要找到对患者有效的联合用药方法。因此，本文旨在探讨分析对多重耐药鲍曼不动杆菌肺炎患者采用替加环素联合头孢哌酮舒巴坦进行治疗的效果。

1  资料和方法

1.1一……